Overview

To date, more than 300 patients have been treated with Glofitamab in the Expanded Access Programme (EAP) in France. In this study, it is proposed to perform a retrospective analysis of some of these patients. The aim is to describe the efficacy and safety of Glofitamab in the largest reported real-world cohort, with an expected median follow-up of more than 9 months. Particular focus will be given to the relapsed or refractory chimeric antigen receptors-T (CAR-T) population to confirm the response rates (CRR: 35-39%) of Glofitamab in this population and to assess the optimal timing of therapy initiation \[8, 15\].

Eligibility

Inclusion Criteria:

• patient enrolled in the French Glofitamab EAP for R/R DLBCL before 2024 November 1st, 2024
• patient who received at least Obinutuzumab pretreatment and one infusion of Glofitamab
• adult patient
• patient who is informed of the study and who did not oppose to their data collection

Exclusion Criteria:

• none